fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Flutamide

All products: general benefit

Flutamide · DIN 02238560 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Flutamide · DIN 02238560 Manufacturer: A A Pharma Inc.; listing date 1999-04-15 Health Canada: Marketed since 2020-05-25 · brand FLUTAMIDE · ATC L02BB01 FLUTAMIDE · form Tablet · route Oral · ingredients FLUTAMIDE 250 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Flutamide: Formulary list price $1.83 per unit (the source does not state the unit; exact figure $1.8255). What the ministry pays, not the patient.

Ministry pays: $1.8255 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238560)

Source record
DIN 02238560: Flutamide Raw flags: sec3=Y Item: 100000050; group id 163; item number 0278; lccId None; manufacturer id AAP Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $1.8255; ministry $1.8255 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238560 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61987
Interchangeable products
Euflex · DIN 00637726 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238560
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L02B, L02BB): coverage varies; not interchangeable

  • Bicalutamide (Casodex): general benefit, not a benefit
  • Enzalutamide (Xtandi): not a benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FLUTAMIDE (flutamide) is indicated:  For use in combination with LHRH agonistic analogues (such as leuprolide acetate) for the treatment of metastatic prostatic carcinoma (stage D2). To achieve the benefit of the adjunctive therapy with FLUTAMIDE, treatment must be started simultaneously using both drugs.  As an adjunctive therapy to orchiectomy, in order to achieve complete androgen blockade.  FLUTAMIDE in combination with LHRH agonists are also indicated prior to and during definitive external beam radiotherapy for patients with bulky locally advanced Stage B 2 and Stage C prostatic carcinoma. See 4 DOSAGE AND ADMINISTRATION. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 8.2 Clinical Trial Adverse Reactions and 10.3 Pharmacokinetics. https://pdf.hres.ca/dpd_pm/00064881.PDF PM date: FEB 25, 2022 Source product: FLUTAMIDE; DIN 02238560; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.